Living Well with CML: An Educational Program for Patients and Caregivers

Novartis Pharmaceuticals
Last Modified: October 7, 2013

Share article

Dates: Saturday, November 2, 2013
Time: 10:00AM-2:00PM EDT

Sponsoring Group: Novartis Pharmaceuticals

Web Page URL:

Topics Covered: CML

Objectives: An educational program on Chronic Myeloid Leukemia (CML)

Who Should Attend: Patients and caregivers

Agenda: Hear from a distinguished hematology/oncology healthcare provider and an experienced social worker Meet NBA Hall of Famer Kareem Abdul-Jabbar Meet others in your region who have CML or who care for someone with CML Ask the experts the questions about CML that are most important to you

Registration Information:

Fees: Free Program and Free Parking

Continuing Education: No

Audience: Patients

Nilotinib, ponatinib appear effective for different types of chronic myeloid leukemia

Dec 7, 2010 - Nilotinib may improve survival in some chronic myeloid leukemia (CML) patients, and patients with various types of CML respond well to ponatinib, according to research being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. Other studies being presented outline the optimal use of imatinib, address how a new gene target functions for several myeloid malignancies, highlight a tool for predicting acute myeloid leukemia outcomes, and address the use of mitoxantrone in acute lymphoblastic leukemia.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More